Summary
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
History
Monopar Therapeutics was founded in 2016 in Cleveland, Ohio to develop therapeutics for cancer and nerve damage. The company's first product, MP1032, is an immune modulating therapy to treat glioblastoma. Monopar has also secured the rights to a portfolio of oncology therapeutics discovered by Eli Lilly and Company.
Mission
Our mission is to develop innovative therapeutics to improve the lives of patients with cancer and nerve damage.
Vision
Our vision is to be the leader in developing and commercializing innovative therapeutics to treat cancer and nerve damage.
Key Team
Dr. Patrice P. Rioux M.D., Ph.D. (Acting Chief Medical Officer)
Recognition and Awards
Monopar Therapeutics has been recognized by the Cleveland Clinic Innovations with the Commercialization Award in 2019, the Biotech and Money Magazine Next Big Thing Award in 2018, and the National Cancer Institute's Small Business Innovation Research Grant in 2017.
References
United States 